Pemetrexed dipotassium heptahydrate is a chemotherapy drug used mainly to treat malignant pleural mesothelioma and non-squamous non-small cell lung cancer (NSCLC). It works as a folate analog metabolic inhibitor, disrupting folate-dependent processes essential for cell replication by inhibiting enzymes involved in the biosynthesis of thymidine and purine nucleotides. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Axtle (TN), L-Glutamic acid, N-[4-[2-(2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo[2, 3-d]pyrimidin-5-yl)ethyl]benzoyl]-, potassium salt and hydrate (1:2:7). Its PubChem CID is 136238656.
Pemetrexed dipotassium heptahydrate
| CAS No | 2668267-29-4 |
|---|---|
| Molecular Formula | C20H33K2N5O13 |
| Molecular Weight | 629.7 g/mol |
| Synonyms | dipotassium;(2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate;heptahydrate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Pemetrexed dipotassium heptahydrate is a chemotherapy drug used mainly to treat malignant pleural mesothelioma and non-squamous non-small cell lung cancer (NSCLC).
The listed CAS number is 2668267-29-4.
The listed molecular formula is C20H33K2N5O13.
The listed molecular weight is 629.7 g/mol.
dipotassium;(2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate;heptahydrate.
The source lists Axtle (TN), L-Glutamic acid, N-[4-[2-(2-amino-4, 7-dihydro-4-oxo-3H-pyrrolo[2, 3-d]pyrimidin-5-yl)ethyl]benzoyl]-, potassium salt and hydrate (1:2:7).